ArticleThe Journal of clinical investigation2009
Genomic amplicons target vesicle recycling in breast cancer.
Article in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- microRNA-205 represses breast cancer metastasis by perturbing the rab coupling protein [RCP]-mediated integrin β1 recycling on the membrane.Apoptosis : an international journal on programmed cell death · 2024Article
- Article
- D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy.Cancers · 2021Article
- RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin.Experimental & molecular medicine · 2018Article
- Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.Experimental & molecular medicine · 2018Article
- Emerging functions of the EGFR in cancer.Molecular oncology · 2018Review
- Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion.Nature communications · 2017Article
- Article
- Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT.Oncotarget · 2016Article
- Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis.Oncotarget · 2015Article
- Integrin traffic - the update.Journal of cell science · 2015Review
- Article
- FER kinase promotes breast cancer metastasis by regulating α6- and β1-integrin-dependent cell adhesion and anoikis resistance.Oncogene · 2013Article
- Endocytosis and cancer.Cold Spring Harbor perspectives in biology · 2013Review
- Regulation of cholesterol biosynthesis and cancer signaling.Current opinion in pharmacology · 2012Review
- Rab25 in cancer: a brief update.Biochemical Society transactions · 2012Review
- Article
- Increased expression of Rab coupling protein in squamous cell carcinoma of the head and neck and its clinical significance.Oncology letters · 2012Article
- Myoferlin depletion in breast cancer cells promotes mesenchymal to epithelial shape change and stalls invasion.PloS one · 2012Article
- Integrative computational biology for cancer research.Human genetics · 2011Review
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
Abstract
Aberrant endocytosis, vesicle targeting, and receptor recycling represent emerging hallmarks of cancer. In this issue of the JCI, Zhang and colleagues demonstrate that RAB-coupling protein (RCP; also known as RAB11FIP1) is a "driver" of the 8p11-12 amplicon in human breast cancer and mouse xenograft models of mammary carcinogenesis (see the related article beginning on page 2171). Their finding that RAB GTPase function enables genomic amplification to confer aggressiveness to mammary tumors adds significantly to the body of evidence supporting pivotal roles for receptor trafficking in the proliferation and metastasis of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.